Clinical Research about Patients Who Use Lobaplatin During Breast Conserving Surgery

Abstract

Objective to study the clinical effect of using Lobaplatin in breast conserving
surgery. Methods: 40 patients who were eligible for breast conserving surgery were selected, and each group was divided into control group and experimental group. In the experimental group, the application of direct spraying and washing compatibility was applied to Lobaplatin, and the control group was washed with the same amount of physiological saline. After surgery, the blood image, liver and kidney function, digestive tract stimulation and wound healing were compared in the two groups, and the long-term metastasis and the recurrence rate were reviewed. Results No statistically significant difference (P> 0.05) in white blood cells and platelet count, serum creatinine and AST, ALT. The wound healing time was similar in the two groups, and there was no significant difference in nausea, vomiting and diarrhea. The recurrence rate in the experimental group was lower than that in the control group (P<0.05). There was no significant difference in distant metastasis. Conclusion: when using Lobaplatin in breast conserving surgery, there is no obvious side effect, obviously reducing the recurrence rate, it is worth popularizing widely.